Pembrolizumab plus chemotherapy as neoadjuvant treatment for high-risk, early-stage triple-negative breast cancer: 60% pathological complete response, high TILs and/or PDL1 = higher pCR. by P Schmid, @LoiSher and coll Tweet added by FabriceAndre @FAndreMD

FabriceAndre

4 years

Pembrolizumab plus chemotherapy as neoadjuvant treatment for high-risk, early-stage triple-negative breast cancer: 60% pathological complete response, high TILs and/or PDL1 = higher pCR. by P Schmid, @LoiSher and coll

1

46

102

Allison Betof Warner, MD, PhD

@DrBetofMDPhD

4 years

@FAndreMD @LoiSher @VasanNeil thoughts??

0

FabriceAndre

@FAndreMD

4 years

@DrVMisra @LoiSher @myESMO I think it s because pdl1/til predict efficacy of the chemo backbone, so in a single arm combo trial the pCR rates are high.

0

5

Replies